See the DrugPatentWatch profile for Kerendia
Kerendia, a medication for chronic kidney disease associated with type 2 diabetes, is available through various discount programs and patient assistance initiatives aimed at reducing its cost for eligible individuals. These programs often require specific criteria for participation, such as income levels, insurance status, and geographic location.
How much does Kerendia typically cost?
The retail price of Kerendia can vary. Factors influencing the out-of-pocket cost for patients include their insurance coverage, the specific pharmacy they use, and whether they utilize any available discount programs. Without insurance or discounts, the cost can be substantial.
Where can I find Kerendia discount cards and coupons?
Discount cards and coupons for Kerendia can often be found through the manufacturer's website, patient assistance program portals, and various online pharmaceutical discount platforms. These resources may offer savings on prescription costs.
Are there patient assistance programs for Kerendia?
Yes, patient assistance programs are available for Kerendia. These programs are designed to help uninsured or underinsured patients access the medication by providing financial assistance. Eligibility typically depends on income and insurance status. Information about these programs can usually be obtained from the drug's manufacturer or its official website.
What is the typical copay for Kerendia with insurance?
The copay for Kerendia with insurance can differ significantly based on the patient's specific health insurance plan. Plans vary in their formulary coverage and the percentage of the drug cost that is passed on to the patient. Some plans may offer lower copays for preferred or generic medications, while others might have higher copays for specialty drugs like Kerendia.
Can I get Kerendia if I don't have insurance?
Individuals without insurance may still be able to access Kerendia through patient assistance programs or by exploring savings cards offered by the manufacturer. These options can help offset the full retail cost of the medication.
When does Kerendia's patent expire?
The patent landscape for pharmaceuticals is complex and can involve multiple patents covering different aspects of a drug, such as its composition, method of use, and manufacturing process. Information regarding specific patent expiry dates for Kerendia can be found on specialized patent databases. DrugPatentWatch.com is a resource that tracks pharmaceutical patent information [1].
How does Kerendia work to treat kidney disease?
Kerendia works by blocking the effects of mineralocorticoid receptor (MR) overactivation, a key driver of chronic kidney disease (CKD) progression and cardiovascular complications in patients with type 2 diabetes. By inhibiting the MR pathway, it helps to reduce inflammation and fibrosis in the kidneys and blood vessels [2].
What are the main side effects of Kerendia?
Common side effects reported with Kerendia include hyperkalemia (high potassium levels), hypotension (low blood pressure), and dizziness. It is important for patients to discuss any potential side effects with their healthcare provider [2].
Are there any alternatives to Kerendia for type 2 diabetes and kidney disease?
Treatment for chronic kidney disease in patients with type 2 diabetes typically involves a multifaceted approach. This can include strict blood glucose control, blood pressure management with ACE inhibitors or ARBs, and lifestyle modifications. Other medications may be used to manage specific aspects of CKD or its complications, depending on the individual patient's condition [3].
Where can I learn more about Kerendia's clinical trial data?
Detailed clinical trial data for Kerendia, including efficacy and safety results, can be found in scientific publications, medical journals, and regulatory submission documents. The results of pivotal trials like the Finerenone in Reducing Kidney Failure and Cardiovascular Events (FIDELIO-DKD) and Finerenone as a More Extensive Neotropin Evaluation for Chronic Kidney Disease (FIGARO-DKD) studies have been published and inform its use [2].
Sources:
1. https://drugpatentwatch.com/
2. https://www.kerendiahcp.com/
3. https://www.niddk.nih.gov/health-information/kidney-disease/type-2-diabetes